Geraniol has reached the end of its authorisation pathway under the EU Biocidal Products Regulation, not because it was found uniquely dangerous, but because no company funded its defence. The premium "natural repellent" segment loses part of its legal footing, while DEET, icaridin, IR3535 and Citriodiol remain approved. What it means for the products on your shelf, and why physical barriers sit outside the chemical review cycle entirely.
A regulatory change is passing quietly through Brussels that will affect millions of European consumers without most of them knowing it.
Geraniol, a plant-derived active ingredient widely used in mosquito repellents marketed as "natural", has reached the end of its authorisation period under the EU Biocidal Products Regulation (BPR) 528/2012. Its support in the review programme for product types 18 (insecticides and arthropod control) and 19 (repellents and attractants) has ended, with no notifier defending it. The European Commission is expected to publish a formal non-approval decision; once it does, products using geraniol as an active substance for those uses can no longer be placed on the EU market, and the transitional provisions that keep existing national registrations alive will come to an end (BPR Article 89).
This is not a recall. Products already on shelves are not immediately seized. But new stock cannot be manufactured or imported for EU sale using the active, and retailers will be expected to phase out existing inventory. For consumers, this raises a straightforward question: is the repellent you currently use still EU-legal?
What Is Geraniol, and Why Is It In Your Repellent?
Geraniol is a naturally occurring organic compound found in plants, extracted from geranium and rose oils. It has demonstrated mosquito-repellent properties in laboratory conditions. Because it derives from plants rather than synthetic chemistry, manufacturers have been able to market products containing it as "natural", "botanical", or "plant-based", a category that commands significant consumer premium, particularly in northern and western European markets where concerns about synthetic chemicals are more pronounced.
The problem is that "natural" and "safe" are not synonyms, and they are certainly not synonyms in EU regulatory terms. The BPR applies the same evidentiary standard to plant-derived active substances as it does to synthetic ones: manufacturers must demonstrate efficacy, safety for humans and the environment, and provide full toxicological dossiers. The regulatory process does not give natural substances a free pass because they come from a geranium rather than a petrochemical facility.
Why Did Geraniol Fail the Review?
The answer is not exactly that it "failed", it is that no company chose to fund its defence.
Under the BPR review programme, approval of an active substance requires an industry notifier, a company or consortium, to submit a comprehensive technical dossier and bear the costs of evaluation (Commission Delegated Regulation (EU) No 1062/2014). For high-volume synthetic actives like DEET or Icaridin, the commercial logic is clear: the investment pays off in continued market access.
For plant extracts like geraniol, the economics are harder. These compounds cannot be patented the way synthetic molecules can, so any manufacturer who funds the approval process effectively creates a public good that competitors can exploit without contributing. The result is a collective-action problem: no single company has sufficient incentive to bear the full cost.
In the case of geraniol, the European Chemicals Agency (ECHA) updated its review-programme list in July 2025 with no notifier supporting the substance's continued approval in product types 18 and 19, and it is now listed as unsupported. The substance is not being removed because it is uniquely dangerous, it is being removed because no one paid for it to stay.
That distinction matters for consumer communication, but it does not change the regulatory outcome: products using geraniol as an active biocidal substance will need to be reformulated or withdrawn.
Which Products Are Affected?
The most directly impacted products are in two BPR product types:
- PT18 (insecticides and products controlling arthropods): Products marketed to kill or incapacitate mosquitoes, sprays, coils, plug-in devices, and surface treatments, that use geraniol as their active (BPR Annex V).
- PT19 (repellents and attractants): Skin-applied or clothing-applied repellents using geraniol (BPR Annex V). This is where the biggest consumer-facing impact will be felt.
Affected product lines include a significant portion of the premium "natural repellent" segment: plant-based sprays, essential-oil repellent bands and clips, citronella-adjacent formulations that blend geraniol with other botanical extracts, and various private-label lines sold by pharmacies, outdoor retailers, and eco-product stores across Europe.
What Is Still EU-Legal?
The EU currently maintains a list of approved active substances for insect repellents; ECHA publishes the list and the status of those under review. As of today, these are:
If your repellent uses one of these four actives as its primary ingredient, it is EU-authorised and can continue to be placed on the market. If it uses geraniol as the stated active substance, it falls into the category that is now losing its authorisation pathway.
How to Check Your Product
The simplest approach is to read the active substance declaration on the packaging. The BPR requires biocidal products to be classified, packaged and labelled to its standard (Article 69). If the product does not list an active substance at all, it may not be authorised as a biocidal product, which raises separate questions about whether its efficacy claims are substantiated.
Products legally authorised under the BPR carry the labelling that the regulation requires. Products that merely contain plant extracts but make no biocidal efficacy claims may be classified differently, as cosmetics, for example, but they also cannot legally claim to repel mosquitoes or provide protection against bites.
When in doubt, check the ECHA biocidal products register.
What This Means for the Wider Market
Today's deadline accelerates a consolidation that has been underway in the EU repellent market for several years. The premium "natural repellent" segment, which grew rapidly through the 2010s on the back of consumer demand for plant-based alternatives, is facing a structural challenge: the ingredients that made its marketing compelling are losing their legal pathway.
This creates pressure in a few directions. Some manufacturers will reformulate around Citriodiol, a plant-derived active approved under the BPR. Others will migrate their products toward DEET or Icaridin and reclassify their positioning. Some will exit the repellent category altogether.
For consumers, the message is straightforward: a product marketed on the basis of geraniol is no longer backed by EU regulatory review of that ingredient. The EU's position is not that this compound is certainly dangerous, it is that the evidence has not been assembled to demonstrate that it is safe and effective to the standard the regulation requires. Given that the purpose of a repellent is to protect you from mosquito-borne disease, that gap matters.
A Different Approach to the Problem
Mosticare builds mosquito protection around a completely different principle: physical barrier. Our products, screens, nets, and structural protection systems, prevent mosquitoes from reaching you without using any biocidal active substance at all. There is no active ingredient to approve, no review cycle to navigate, no risk of reformulation. Physical barriers work by mechanical exclusion, not chemical repulsion, and the EU has no plans to regulate geometry.
This is not a coincidence of design. Physical protection is the most durable and broadly applicable form of mosquito defence precisely because it operates outside the chemical regulatory cycle. As active-substance approvals become harder to obtain and maintain, the reliability of physical barriers becomes more valuable.
Sources: EU BPR Regulation 528/2012 | Commission Delegated Regulation (EU) No 1062/2014 | ECHA Biocidal Active Substances List | EUR-Lex BPR summary
Mosticare Editorial is the writing arm of Mosticare.